Department of Radiation Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China
Abstract： Objective To evaluate the value of postmastectomy radiotherapy (PMRT) in locally advanced breast cancer patients treated with neoadjuvant chemotherapy (neoCT) and modified radical mastectomy, and to investigate the possibility of individualized radiotherapy according to the response to neoCT. Methods We analyzed 523 patients with stage ⅢA and ⅢB breast cancer who received neoCT and modified radical mastectomy in our hospital from 1999 to 2013. Of all patients, 404 received PMRT, and 119 did not. The locoregional recurrence (LRR), disease-free survival (DFS), and overall survival (OS) rates were calculated using the Kaplan-Meier method, survival difference analysis and univariate prognostic analysis were performed using the log-rank test, and multivariate prognostic analysis was performed using the Cox regression model. Results Compared with those not treated with PMRT, the patients treated with PMRT had a significantly lower 5-year LRR rate (13.9% vs. 24.8%, P=0.013), a significantly higher DFS rate (64.1% vs. 53.9%, P=0.048), and an insignificantly higher OS rate (83.2% vs. 78.2%, P=0.389). In the patients with ypT3-T4, ypN2-N3, or pathologic stage Ⅲ disease, those treated with PMRT had a significantly reduced 5-year LRR rate (P<0.05) and a significantly increased 5-year OS rate (P<0.05), as compared with those not treated with PMRT. Among the 158 patients with ypN0 disease, the 5-year LRR rate was significantly lower in those treated with PMRT than in those not treated with PMRT (P=0.004). Of 41 patients who achieved a pathologic complete response, 2 patients, who did not receive PMRT, developed LRR. The multivariate prognostic analysis indicated that PMRT was an independent prognostic factor associated with reduced LRR in all patients and ypN0 patients. Conclusions In patients with stage ⅢA and ⅢB breast cancer treated with neoCT and modified radical mastectomy, PMRT can significantly reduce LRR for all patients and can reduce both recurrence and mortality for those with ypT3-T4, ypN2-N3, or pathologic stage Ⅲ disease. There is no sufficient evidence that PMRT can be omitted safely for ypN0 or pCR patients according to their response to neoCT.
Rong Qinglin,Wang Shulian,Tang Yu et al. Value of postmastectomy radiotherapy in locally advanced breast cancer patients treated with neoadjuvant chemotherapy and modified radical mastectomy[J]. Chinese Journal of Radiation Oncology, 2017, 26(8): 884-891.
[1] Whelan TJ,Olivotto IA,Parulekar WR,et al. Regional nodal irradiation in early-stage breast cancer[J].N Engl J Med,2015,373(4):307-316.DOI:10.1056/NEJMoa1415340. [2] Poortmans PM,Collette S,Kirkove C,et al. Internal mammary and medial supraclavicular irradiation in breast cancer[J].N Engl J Med,2015,373(4):317-327.DOI:10.1056/NEJMoa1415369. [3] Early Breast Cancer Trialists′ Collaborative Group (EBCTCG).Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:an overview of the randomised trials[J].Lancet,2005,366(9503):2087-2106.DOI:10.1016/S0140-6736(05)67887-7. [4] Buchholz TA,Katz A,Strom EA,et al. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy[J].Int J Radiat Oncol Biol Phys,2002,53(4):880-888.DOI:10.1016/S0360-3016(02)02850-X. [5] Rastogi P,Anderson SJ,Bear HD,et al. Preoperative chemotherapy:updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27[J].J Clin Oncol,2008,26(5):778-785.DOI:10.1200/JCO.2007.15.0235. [6] Mamounas EP,Anderson SJ,Dignam JJ,et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy:results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27[J].J Clin Oncol,2012,30(32):3960-3966.DOI:10.1200/JCO.2011.40.8369. [7] Jeruss JS,Mittendorf EA,Tucker SL,et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy[J].J Clin Oncol,2008,26(2):246-252.DOI:10.1200/JCO.2007.11.5352. [8] von Minckwitz G,Untch M,Blohmer JU,et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes[J].J Clin Oncol,2012,30(15):1796-1804.DOI:10.1200/JCO.2011.38.8595. [9] Overgaard M,Hansen PS,Overgaard J,et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy[J].N Engl J Med,1997,337(14):949-955.DOI:10.1056/NEJM199710023371401. [10] Overgaard M,Jensen MB,Overgaard J,et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen:danish breast cancer cooperative group DBCG 82c randomised trial[J].Lancet,1999,353(9165):1641-1648.DOI:10.1016/S0140-6736(98)09201-0. [11] Ragaz J,Olivotto IA,Spinelli JJ,et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy:20-year results of the British Columbia randomized trial[J].J Natl Cancer Inst,2005,97(2):116-126.DOI:10.1093/jnci/djh297. [12] Huang EH,Tucker SL,Strom EA,et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy[J].J Clin Oncol,2004,22(23):4691-4699.DOI:10.1200/JCO.2004.11.129. [13] Garg AK,Oh JL,Oswald MJ,et al. Effect of postmastectomy radiotherapy in patients<35 years old with stage Ⅱ-Ⅲ breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy[J].Int J Radiat Oncol Biol Phys,2007,69(5):1478-1483.DOI:10.1016/j.ijrobp.2007.05.029. [14] Cortazar P,Zhang LJ,Untch M,et al. Pathological complete response and long-term clinical benefit in breast cancer:the CTNeoBC pooled analysis[J].Lancet,2014,384(9938):164-172.DOI:10.1016/S0140-6736(13)62422-8. [15] Yang TJ,Morrow M,Modi S,et al. The Effect of molecular subtype and residual disease on locoregional recurrence in breast cancer patients treated with neoadjuvant chemotherapy and postmastectomy radiation[J].Ann Surg Oncol,2015,22 Suppl 3:S495-S501.DOI:10.1245/s10434-015-4697-7. [16] McGuire SE,Gonzalez-Angulo AM,Huang EH,et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy[J].Int J Radiat Oncol Biol Phys,2007,68(4):1004-1009.DOI:10.1016/j.ijrobp.2007.01.023. [17] Le Scodan R,Selz J,Stevens D,et al. Radiotherapy for stage Ⅱ and stage Ⅲ breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy[J].Int J Radiat Oncol Biol Phys,2012,82(1):e1-e7.DOI:10.1016/j.ijrobp.2010.12.054. [18] Shim SJ,Park W,Huh SJ,et al. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage Ⅱ-Ⅲ breast cancer patients with pNo:a multicenter,retrospective study (KROG 12-05)[J].Int J Radiat Oncol Biol Phys,2014,88(1):65-72.DOI:10.1016/j.ijrobp.2013.09.021. [19] Early Breast Cancer Trialists′ Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists′ Collaborative Group[J].N Engl J Med,1995,333(22):1444-1456.DOI:10.1056/NEJM199511303332202. [20] Flather MD,Yusuf S,Kober L,et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction:a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group[J].Lancet,2000,355(9215):1575-1581.DOI:10.1016/S0140-6736(00)02212-1.
2017, Vol. 26 
